Literature DB >> 35342478

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.

C Capatina1, C Poiana1.   

Abstract

Non-functioning pituitary tumors (NFPA) are usually large at the time of diagnosis and present with symptoms caused by compression on the neighbouring structures. Transsphenoidal resection of the tumor is the first-line treatment but in many cases complete tumor resection cannot be attained. Close follow-up with repeated hormonal assessment and pituitary imaging is recommended after surgery. During follow-up of the tumor remnant sometimes radiotherapy is used to stop or prevent tumor progression. Medical treatment with dopamine agonists (DA) is the mainstay in the management of prolactinomas. For NFPA several small series or case reports suggested beneficial effects with tumor shrinkage in some cases. The aim of the current paper is to summarize the available evidence related to the potential efficacy of DA medical treatment in NFPA while underlining that in the absence of randomized, placebo-controlled studies, no final conclusion on the efficacy of these drugs in the treatment of NFPA can be drawn. ©2021 Acta Endocrinologica (Buc).

Entities:  

Keywords:  adenomas; dopamine agonists; non-functioning; pituitary

Year:  2021        PMID: 35342478      PMCID: PMC8919496          DOI: 10.4183/aeb.2021.377

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  49 in total

1.  Dopamine receptor expression and function in corticotroph pituitary tumors.

Authors:  Rosario Pivonello; Diego Ferone; Wouter W de Herder; Johan M Kros; Maria Laura Del Basso De Caro; Marica Arvigo; Lucio Annunziato; Gaetano Lombardi; Annamaria Colao; Leo J Hofland; Steven W J Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

2.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

3.  Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas.

Authors:  Marek Pawlikowski
Journal:  Folia Histochem Cytobiol       Date:  2010-09-30       Impact factor: 1.698

4.  Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors.

Authors:  A Klibanski; M A Shupnik; H A Bikkal; P M Black; B Kliman; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

5.  Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture.

Authors:  D J Kwekkeboom; L J Hofland; P M van Koetsveld; R Singh; J H van den Berge; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

6.  Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.

Authors:  Y Greenman; O Cooper; I Yaish; E Robenshtok; N Sagiv; T Jonas-Kimchi; X Yuan; A Gertych; I Shimon; Z Ram; S Melmed; N Stern
Journal:  Eur J Endocrinol       Date:  2016-05-05       Impact factor: 6.664

7.  Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers.

Authors:  Metaxia Tampourlou; Georgia Ntali; Shahzada Ahmed; Wiebke Arlt; John Ayuk; James V Byrne; Swarupsinh Chavda; Simon Cudlip; Neil Gittoes; Ashley Grossman; Rosalind Mitchell; Michael W O'Reilly; Alessandro Paluzzi; Andrew Toogood; John A H Wass; Niki Karavitaki
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 5.958

8.  Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.

Authors:  D Ferone; S Lastoria; A Colao; P Varrella; G Cerbone; W Acampa; B Merola; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

9.  Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma.

Authors:  F R Nobels; W W de Herder; W M van den Brink; D J Kwekkeboom; L J Hofland; J Zuyderwijk; F H de Jong; S W Lamberts
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

10.  Bromocriptine therapy for "nonfunctioning" pituitary tumors.

Authors:  D G Johnston; K Hall; A McGregor; W M Ross; P Kendall-Taylor; R Hall
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.